Pilot Study of an Alpha-2-Macroglobulin-Enriched Plasma-Derived Orthobiologic Preparation in Sport Horses with Chronic Degenerative Joint Disease.

Overview

• This study explored whether injecting a plasma-derived treatment rich in alpha-2-macroglobulin could improve symptoms and joint health markers in sport horses suffering from chronic degenerative joint disease.
• The researchers compared clinical improvements and biomarker changes in treated horses to a comparison group over a period of up to 180 days.

Background and Purpose

• Chronic degenerative joint disease causes ongoing joint inflammation and deterioration in sport horses, leading to lameness and poor performance.
• The disease involves persistent synovial (joint lining) inflammation and breakdown of joint cartilage by proteases (enzymes that degrade proteins in joint tissue).
• Alpha-2-macroglobulin is a plasma protein that can inhibit various proteases, potentially protecting joint cartilage from degradation.
• This pilot study aimed to test a new orthobiologic treatment—an alpha-2-macroglobulin enriched plasma preparation—administered directly into the joint to assess its effects on clinical symptoms and biochemical markers of joint health.

Study Design and Methods

• The study was prospective and exploratory, utilizing a pilot design to generate initial data.
• Twenty client-owned sport horses with chronic joint disease were enrolled and divided into two groups: treatment (n = 10) and comparison (n = 10).
• Treated horses received an intra-articular injection of the alpha-2-macroglobulin-enriched plasma preparation.
• Clinical evaluations were performed repeatedly for up to 180 days under normal field conditions to assess lameness severity, flexion test response, and joint effusion (swelling).
• Synovial fluid samples were taken at baseline and 30 days post-treatment from treated horses to measure biomarkers related to inflammation, immune cell counts, enzyme activity, and neurogenic inflammation mediators.
• Comparison group did not receive the treatment, and biomarker sampling was not performed on them.
• Data was analyzed using mixed-effects statistical models to understand interactions between group and time effects.

Key Clinical Findings

• Treated horses showed significant and sustained improvement in AAEP lameness scores over time compared to the comparison group.
• Improvement was similarly noted in flexion test responses, indicating reduced joint pain and increased joint function in treated horses.
• Joint effusion was reduced in treated horses, suggesting reduced inflammation and swelling.
• The comparison group showed minimal changes in clinical signs over the same period, reinforcing that observed improvements were associated with treatment.

Synovial Biomarker Changes in Treated Horses

• 30 days post-treatment, there were consistent decreases in synovial fluid total protein and total nucleated cell count, indicating reduced inflammatory response.
• The percentage of polynuclear cells (a type of immune cell involved in acute inflammation) was also reduced.
• Pro-inflammatory cytokines such as prostaglandin E (PGE), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β) showed marked reductions, suggesting lowered inflammation within the joint.
• Matrix metalloproteinases MMP-9 and MMP-13, which degrade cartilage and extracellular matrix, were decreased, indicating potential slowing of joint tissue breakdown.
• Levels of sulphated glycosaminoglycans (components of cartilage matrix) decreased, which may reflect reduced matrix turnover or cartilage degradation.
• Neurogenic inflammation markers such as nerve growth factor (NGF) and Substance P were also reduced, which aligns with reported pain relief.

Interpretation and Limitations

• The combination of clinical improvements with parallel reductions in inflammatory and degradative biomarkers supports the biological activity of the alpha-2-macroglobulin treatment in improving joint conditions.
• The study’s exploratory design and lack of biomarker data from the comparison group limit the ability to conclusively attribute the observed changes to treatment alone.
• Longitudinal biomarker data from untreated horses would be necessary to establish causality definitively.
• Nonetheless, results justify further, more rigorous studies investigating protease inhibition and related approaches in managing equine joint disease.

Conclusions and Future Directions

• Alpha-2-macroglobulin-enriched plasma injection showed promising results in reducing lameness and inflammatory markers in sport horses with chronic joint disease.
• By targeting protease activity, this treatment may help slow joint degradation and reduce pain, offering a novel therapeutic avenue.
• Further studies with larger cohorts, controlled designs, and more comprehensive biomarker monitoring are needed to confirm efficacy and elucidate mechanisms.
• This research contributes foundational data supporting protease-targeted orthobiologic therapies in equine medicine.